Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Correction of Androgen Deficiency in Men with Type 2 Diabetes

Author(s): Volodymyr Pankiv , Tetyana Yuzvenko, Nazarii Kobyliak* and Ivan Pankiv

Volume 17, Issue 1, 2022

Published on: 01 February, 2022

Page: [34 - 39] Pages: 6

DOI: 10.2174/1574887116666211202155304

Price: $65

Abstract

Background: In men with low levels of testosterone in the blood, it is believed that the symptoms can be regarded as an association between testosterone deficiency syndrome and related comorbidities.

Aim: To investigate the effectiveness of testosterone therapy in patients with type 2 diabetes (T2D) and androgen deficiency.

Materials and Methods: Testosterone replacement therapy was carried out in 26 men with T2D and clinically or laboratory-confirmed androgen deficiency. The age of the subjects ranged from 35 to 69 years old. Laboratory studies included determinations of the concentration of the hormones estradiol, luteinizing hormone (LH), and prostate-specific antigen (PSA). The observation period was 9 months.

Results: The average level of total blood testosterone in the subjects before treatment was 9.4 mol/l and was likely lower than that of the control group (19.3 ± 1.6 nmol/l). The levels of total testosterone in the subjects ranged from 3.9 nmol/l to 10.7 nmol/l, and hormone levels measuring less than 8.0 nmol/l were observed in only 11 patients. After a course of testosterone replacement therapy, a stabilization in total testosterone levels at the level of reference values (as compared to the start of treatment) was observed in the blood of men with T2D after 9 months of observation and the administration of the fourth injection (16.83 ± 0.75 nmol/l).

Conclusion: The use of long-acting injectable testosterone undecanoate leads to normalization of total testosterone levels in the blood of men with T2D and androgen deficiency, and LH levels in these patients are unlikely to change.

Keywords: Type 2 diabetes, androgen deficiency, testosterone undecanoate, metabolic disorders, estradiol, sexual dysfunction, chronic fatigue.

« Previous Next »
Graphical Abstract

[1]
McBride JA, Carson CC III, Coward RM. Testosterone deficiency in the aging male. Ther Adv Urol 2016; 8(1): 47-60.
[http://dx.doi.org/10.1177/1756287215612961] [PMID: 26834840]
[2]
Vesper HW, Wang Y, Vidal M, Botelho JC, Caudill SP. Serum total testosterone concentrations in the US household population from the NHANES 2011-2012 study population. Clin Chem 2015; 61(12): 1495-504.
[http://dx.doi.org/10.1373/clinchem.2015.245969] [PMID: 26510959]
[3]
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018; 103(5): 1715-44.
[http://dx.doi.org/10.1210/jc.2018-00229] [PMID: 29562364]
[4]
Paduch DA, Brannigan RE, Fuchs EF, Kim ED, Marmar JL, Sandlow JI. The laboratory diagnosis of testosterone deficiency. Urology 2014; 83(5): 980-8.
[http://dx.doi.org/10.1016/j.urology.2013.12.024] [PMID: 24548716]
[5]
Hackney AC. Hypogonadism in exercising males: Dysfunction or adaptive-regulatory adjustment? Front Endocrinol (Lausanne) 2020; 11: 11.
[http://dx.doi.org/10.3389/fendo.2020.00011] [PMID: 32082255]
[6]
Rey RA, Grinspon RP, Gottlieb S, et al. Male hypogonadism: An extended classification based on a developmental, endocrine physiology-based approach. Andrology 2013; 1(1): 3-16.
[http://dx.doi.org/10.1111/j.2047-2927.2012.00008.x] [PMID: 23258624]
[7]
Holmboe SA, Skakkebæk NE, Juul A, et al. Individual testosterone decline and future mortality risk in men. Eur J Endocrinol 2018; 178(1): 123-30.
[http://dx.doi.org/10.1530/EJE-17-0280] [PMID: 29066571]
[8]
Sterling J, Bernie AM, Ramasamy R. Hypogonadism: Easy to define, hard to diagnose, and controversial to treat. Can Urol Assoc J 2015; 9(1-2): 65-8.
[http://dx.doi.org/10.5489/cuaj.2416] [PMID: 25737761]
[9]
Saad F, Caliber M, Doros G, Haider KS, Haider A. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male 2020; 23(1): 81-92.
[http://dx.doi.org/10.1080/13685538.2019.1575354] [PMID: 30782054]
[10]
American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44(Suppl. 1): S15-33.
[http://dx.doi.org/10.2337/dc21-S002] [PMID: 33298413]
[11]
Saad F, Doros G, Haider KS, Haider A. Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms. Investig Clin Urol 2018; 59(6): 399-409.
[http://dx.doi.org/10.4111/icu.2018.59.6.399] [PMID: 30402573]
[12]
Gianatti EJ, Grossmann M. Testosterone deficiency in men with Type 2 diabetes: Pathophysiology and treatment. Diabet Med 2020; 37(2): 174-86.
[http://dx.doi.org/10.1111/dme.13977] [PMID: 31006133]
[13]
Pastuszak AW, Hu Y, Freid JD. occurrence of pulmonary oil microembolism after testosterone undecanoate injection: A postmarketing safety analysis. Sex Med 2020; 8(2): 237-42.
[http://dx.doi.org/10.1016/j.esxm.2020.01.009] [PMID: 32184081]
[14]
Middleton T, Turner L, Fennell C, et al. Complications of injectable testosterone undecanoate in routine clinical practice. Eur J Endocrinol 2015; 172(5): 511-7.
[http://dx.doi.org/10.1530/EJE-14-0891] [PMID: 25637074]
[15]
Krakowsky Y, Conners W, Davidson E, Rawji A, Morgentaler A. Initial clinical experience with testosterone undecanoate therapy (AVEED) in men with testosterone deficiency in the United States. Urology 2017; 109: 27-31.
[http://dx.doi.org/10.1016/j.urology.2017.07.007] [PMID: 28735014]
[16]
Rogerson S, Weatherby RP, Deakin GB, et al. The effect of short-term use of testosterone enanthate on muscular strength and power in healthy young men. J Strength Cond Res 2007; 21(2): 354-61.
[http://dx.doi.org/10.1519/R-18385.1] [PMID: 17530941]
[17]
Camozzi V, Bonanni G, Frigo A, et al. Effect of a single injection of testosterone enanthate on 17β estradiol and bone turnover markers in hypogonadal male patients. J Endocrinol Invest 2015; 38(4): 389-97.
[http://dx.doi.org/10.1007/s40618-014-0183-5] [PMID: 25319469]
[18]
Yeo S, Holl K, Peñaherrera N, Wissinger U, Anstee K, Wyn R. Burden of male hypogonadism and major comorbidities, and the clinical, economic, and humanistic benefits of testosterone therapy: A narrative review. Clinicoecon Outcomes Res 2021; 13: 31-8.
[http://dx.doi.org/10.2147/CEOR.S285434] [PMID: 33488103]
[19]
Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol 2017; 72(6): 1000-11.
[http://dx.doi.org/10.1016/j.eururo.2017.03.032] [PMID: 28434676]
[20]
Aversa A, Morgentaler A. The practical management of testosterone deficiency in men. Nat Rev Urol 2015; 12(11): 641-50.
[http://dx.doi.org/10.1038/nrurol.2015.238] [PMID: 26458755]
[21]
Kobyliak NM, Falalyeyeva TM, Kuryk OG, et al. Antioxidative effects of cerium dioxide nanoparticles ameliorate age-related male infertility: Optimistic results in rats and the review of clinical clues for integrative concept of men health and fertility. EPMA J 2015; 6(1): 12.
[http://dx.doi.org/10.1186/s13167-015-0034-2] [PMID: 26097523]
[22]
Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU Int 2016; 118(5): 804-13.
[http://dx.doi.org/10.1111/bju.13516] [PMID: 27124889]

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy